[{"NetIncomeLoss_1_Q1_USD":-16381000.0,"PreferredStockSharesOutstanding_0_Q1_shares":1164000.0,"GeneralAndAdministrativeExpense_1_Q1_USD":3847000.0,"AccumulatedOtherComprehensiveIncomeLossNetOfTax_0_Q1_USD":-48168000.0,"NetCashProvidedByUsedInInvestingActivities_1_Q1_USD":18221000.0,"Depreciation_1_Q1_USD":443000.0,"StockIssuedDuringPeriodValueNewIssues_1_Q1_USD":26419000.0,"PaymentsToAcquireInvestments_1_Q1_USD":2030000.0,"AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedLossBeforeTax_0_Q1_USD":0.0,"EquityMethodInvestments_0_Q1_USD":0.0,"AccountsPayableAndAccruedLiabilitiesCurrent_0_Q1_USD":6063000.0,"RestructuringCharges_1_Q1_USD":0.0,"AntidilutiveSecuritiesExcludedFromComputationOfEarningsPerShareAmount_1_Q1_shares":35000000.0,"StockIssuedDuringPeriodValueStockOptionsExercised_1_Q1_USD":208000.0,"CommonStockSharesIssued_0_Q1_shares":96245371.0,"AvailableForSaleSecuritiesDebtSecurities_0_Q1_USD":52540000.0,"Assets_0_Q1_USD":146240000.0,"OtherComprehensiveIncomeLossNetOfTax_1_Q1_USD":3000.0,"ShareBasedCompensation_1_Q1_USD":1635000.0,"AssetsCurrent_0_Q1_USD":137341000.0,"Liabilities_0_Q1_USD":32091000.0,"ProceedsFromSaleMaturityAndCollectionsOfInvestments_1_Q1_USD":20350000.0,"OperatingLeaseLiabilityNoncurrent_0_Q1_USD":2477000.0,"EarningsPerShareBasic_1_Q1_USD":-0.21,"EffectOfExchangeRateOnCashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_1_Q1_USD":-44000.0,"WeightedAverageNumberOfDilutedSharesOutstanding_1_Q1_shares":93434378.0,"ProceedsFromStockPlans_1_Q1_USD":247000.0,"AccountsReceivableNetCurrent_0_Q1_USD":1265000.0,"NumberOfReportableSegments_1_Q1_numberOfSegments":1.0,"CommonStockValue_0_Q1_USD":1013118000.0,"Revenues_1_Q1_USD":2113000.0,"IncreaseDecreaseInAccountsPayableAndAccruedLiabilities_1_Q1_USD":-2796000.0,"DepreciationDepletionAndAmortization_1_Q1_USD":443000.0,"ForeignCurrencyTransactionGainLossBeforeTax_1_Q1_USD":28000.0,"ForeignCurrencyTransactionGainLossUnrealized_1_Q1_USD":-44000.0,"NetCashProvidedByUsedInFinancingActivities_1_Q1_USD":26874000.0,"BusinessCombinationContingentConsiderationArrangementsChangeInAmountOfContingentConsiderationLiability1_1_Q1_USD":129000.0,"CashCashEquivalentsAndShortTermInvestments_0_Q1_USD":132000000.0,"NetIncomeLossAvailableToCommonStockholdersBasic_1_Q1_USD":-19593000.0,"ComprehensiveIncomeNetOfTax_1_Q1_USD":-16378000.0,"OtherAssetsNoncurrent_0_Q1_USD":0.0,"CashAndCashEquivalentsAtCarryingValue_0_Q1_USD":79421000.0,"OperatingLeaseRightOfUseAsset_0_Q1_USD":2315000.0,"ProceedsFromIssuanceOfCommonStock_1_Q1_USD":26419000.0,"DebtSecuritiesAvailableForSaleUnrealizedGainLoss_1_Q1_USD":3000.0,"PreferredStockAccretionOfRedemptionDiscount_1_Q1_USD":0.0,"AvailableForSaleDebtSecuritiesAccumulatedGrossUnrealizedGainBeforeTax_0_Q1_USD":17000.0,"IncomeLossFromContinuingOperationsBeforeIncomeTaxesExtraordinaryItemsNoncontrollingInterest_1_Q1_USD":-16381000.0,"AdjustmentsToAdditionalPaidInCapitalSharebasedCompensationRequisiteServicePeriodRecognitionValue_1_Q1_USD":1647000.0,"NetCashProvidedByUsedInOperatingActivities_1_Q1_USD":-17881000.0,"WeightedAverageNumberOfSharesOutstandingBasic_1_Q1_shares":93434378.0,"LiabilitiesCurrent_0_Q1_USD":6693000.0,"NonoperatingIncomeExpense_1_Q1_USD":-705000.0,"InterestExpense_1_Q1_USD":772000.0,"CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalents_0_Q1_USD":79421000.0,"PrepaidExpenseAndOtherAssetsCurrent_0_Q1_USD":4115000.0,"ProceedsFromStockOptionsExercised_1_Q1_USD":208000.0,"OtherAccruedLiabilitiesCurrent_0_Q1_USD":10000.0,"PreferredStockIncludingAdditionalPaidInCapitalNetOfDiscount_0_Q1_USD":152620000.0,"AdditionalPaidInCapital_0_Q1_USD":62133000.0,"DebtSecuritiesRealizedGainLoss_1_Q1_USD":0.0,"StockIssuedDuringPeriodValueEmployeeStockPurchasePlan_1_Q1_USD":247000.0,"PreferredStockSharesIssued_0_Q1_shares":1164000.0,"BusinessCombinationContingentConsiderationLiabilityNoncurrent_0_Q1_USD":3555000.0,"PropertyPlantAndEquipmentNet_0_Q1_USD":6584000.0,"AccumulatedDepreciationDepletionAndAmortizationPropertyPlantAndEquipment_0_Q1_USD":8063000.0,"ResearchAndDevelopmentExpense_1_Q1_USD":13370000.0,"PreferredStockDividendsAndOtherAdjustments_1_Q1_USD":3212000.0,"EarningsPerShareDiluted_1_Q1_USD":-0.21,"IncreaseDecreaseInPrepaidDeferredExpenseAndOtherAssets_1_Q1_USD":857000.0,"OperatingIncomeLoss_1_Q1_USD":-15676000.0,"AccountsPayableTradeCurrent_0_Q1_USD":355000.0,"AvailableForSaleSecuritiesDebtSecuritiesCurrent_0_Q1_USD":52540000.0,"InvestmentIncomeInterest_1_Q1_USD":39000.0,"ShareBasedCompensationArrangementsByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageExercisePrice_1_Q1_USD":4.33,"LiabilitiesAndStockholdersEquity_0_Q1_USD":146240000.0,"AllocatedShareBasedCompensationExpense_1_Q1_USD":1635000.0,"OperatingLeaseLiabilityCurrent_0_Q1_USD":432000.0,"OperatingExpenses_1_Q1_USD":17789000.0,"StockholdersEquity_0_Q1_USD":114149000.0,"PaymentsToAcquirePropertyPlantAndEquipment_1_Q1_USD":99000.0,"AvailableForSaleDebtSecuritiesAmortizedCostBasis_0_Q1_USD":52523000.0,"AccretionAmortizationOfDiscountsAndPremiumsInvestments_1_Q1_USD":-159000.0,"IncreaseDecreaseInOtherOperatingLiabilities_1_Q1_USD":-116000.0,"RetainedEarningsAccumulatedDeficit_0_Q1_USD":-1065554000.0,"CashCashEquivalentsRestrictedCashAndRestrictedCashEquivalentsPeriodIncreaseDecreaseIncludingExchangeRateEffect_1_Q1_USD":27170000.0,"IncreaseDecreaseInAccountsReceivable_1_Q1_USD":-47000.0,"CommonStockSharesOutstanding_0_Q1_shares":96245371.0,"DividendsPreferredStockCash_1_Q1_USD":3212000.0,"AccruedProfessionalFeesCurrent_0_Q1_USD":690000.0,"Ticker":"ABUS","CIK":"1447028","name":"ARBUTUS BIOPHARMA CORP","OfficialName":"Arbutus Biopharma Corporation Common Stock","form":"10-Q","period":"20210331","fy":"2021.0","fp":"Q1","qtrs":"1","uom":"USD","footnote":"nan","Market Cap":"388180699.0","Country":"Canada","Sector":"nan","Industry":"nan","Market":"NASDAQ","SP500":"nan","filed":"20210505"}]